The business address of the Reporting Persons is c/o Las Vegas Sands Corp., 5420 S. Durango Dr., Las Vegas, Nevada, 89113.

The present principal occupations of the Reporting Persons are: (i) Dr. Adelson: Physician. (ii) Mr. Chafetz: Member of the Board of Directors of the Issuer and manager of The Interface Group, LLC, a Massachusetts limited liability company. (iii) Ms. Dumont: Investor. (iv) ESBT S Trust: Not applicable. (v) ESBT S-II Trust: Not applicable. (vi) ESBT Y-II Trust: Not applicable. (vii) QSST A-II Trust: Not applicable. (viii) QSST M-II Trust: Not applicable.

During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

During the last five years, none of the Reporting Persons has been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(i) Dr. Adelson is a citizen of the United States and Israel. (ii) Mr. Chafetz is a citizen of the United States. (iii) Ms. Dumont is a citizen of the United States and Israel. (iv) ESBT S Trust is organized under the laws of Nevada. (v) ESBT S-II Trust is organized under the laws of Nevada. (vi) ESBT Y-II Trust is organized under the laws of Nevada. (vii) QSST A-II Trust is organized under the laws of Nevada. (viii) QSST M-II Trust is organized under the laws of Nevada.

Item 3 of the Schedule 13D is hereby amended by adding the text below to the end of Item 3 of the Schedule 13D. On August 7, 2026, ESBT S-II Trust transferred 43,859,460 shares of the Issuer's Common Stock for no consideration to ESBT S Trust. As a result of the transfer, as of the date of this Amendment, ESBT S-II Trust no longer beneficially owns any share of the Issuer's Common Stock, and ESBT S Trust and Ms. Dumont beneficially own 46,674,403 and 57,136,031 shares of the Issuer's Common Stock, respectively.

Item 4 of the Schedule 13D is hereby amended by adding the text below to the end of Item 4 of the Schedule 13D. The Issuer has historically maintained a share repurchase program for the repurchase of shares of its Common Stock from time to time. As a result of repurchases under this program, the number of shares of outstanding Common Stock has decreased, and consequently, the percentages of shares of Common Stock beneficially owned by certain of the Reporting Persons have passively increased. ESBT S Trust and Ms. Dumont adopt the disclosure made by the other Reporting Persons in Item 4 of the Schedule 13D.

Item 5(a) of the Schedule 13D is hereby amended and restated as follows: The responses of the Reporting Persons to Rows (11) and (13) of the cover page of this Amendment are incorporated herein by reference. Each Reporting Person may be deemed to beneficially own the shares of Common Stock beneficially owned by the other Reporting Persons but disclaims such beneficial ownership. The beneficial ownership of all of the Reporting Persons together is 386,728,789 shares of Common Stock, or 59.7% of the Outstanding Common Stock.

Item 5(b) of the Schedule 13D is hereby amended and restated as follows: Dr. Adelson beneficially owns an aggregate of 341,442,911 shares of Common Stock (approximately 52.7% of the Outstanding Common Stock). Of these shares, (i) 46,674,403 shares are held by ESBT S Trust, (ii) 43,859,459 shares are held by ESBT Y-II Trust, (iii) 43,859,459 shares are held by QSST A-II Trust, (iv) 43,859,459 shares are held by QSST M-II Trust, (v) 561,578 shares are issuable upon the exercise of options held by The Miriam Adelson Trust that are exercisable currently and (vi) 162,628,553 shares are held by various entities as described below. Dr. Adelson has sole voting control over 48,767,951 shares of Common Stock, of which (i) 561,578 shares are issuable upon the exercise of options held by The Miriam Adelson Trust that are exercisable currently and (ii) 48,206,373 shares are held by various entities as described below. Dr. Adelson has shared voting control over 2,208,548 shares of Common Stock. Dr. Adelson has sole dispositive power over 92,496,223 shares of Common Stock, of which (i) 561,578 shares are issuable upon the exercise of options held by The Miriam Adelson Trust that are exercisable currently and (ii) 91,934,645 shares are held by various entities as described below. Dr. Adelson has shared dispositive control over 248,946,688 shares of Common Stock, of which (i) 46,674,403 shares are held by ESBT S Trust, (ii) 43,859,459 shares are held by ESBT Y-II Trust, (iii) 43,859,459 shares are held by QSST A-II Trust, (iv) 43,859,459 shares are held by QSST M-II Trust and (v) 70,693,908 shares are held by various entities as described below. Mr. Chafetz is deemed to beneficially own an aggregate of 337,960,838 shares of Common Stock (approximately 52.2% of the Outstanding Common Stock). Of these shares, (i) 70,949 shares are owned directly by Mr. Chafetz and (ii) 337,889,889 shares are held by various entities as described below, with respect to which he is deemed to have a beneficial interest by virtue of the interest and authority granted to him under the trust instruments or organizational documents, as applicable. Mr. Chafetz disclaims beneficial ownership of those shares of Common Stock not owned directly by him. Mr. Chafetz has sole voting control over 335,752,290 shares of Common Stock, of which (i) 70,949 shares are owned directly by Mr. Chafetz and (ii) 335,681,341 shares are held by various entities as described below. Mr. Chafetz has shared voting control over 2,208,548 shares of Common Stock. Mr. Chafetz has sole dispositive control over 43,935,878 shares of Common Stock, of which (i) 70,949 shares are owned directly by Mr. Chafetz and (ii) 43,864,929 shares are held by various entities as described below. Mr. Chafetz has shared dispositive control over 239,835,060 shares of Common Stock, of which (i) 46,674,403 shares are held by ESBT S Trust, (ii) 43,859,459 shares are held by ESBT Y-II Trust, (iii) 43,859,459 shares are held by QSST A-II Trust, (iv) 43,859,459 shares are held by QSST M-II Trust and (v) 61,582,280 shares are held by various entities as described below. Ms. Dumont is deemed to beneficially own an aggregate of 57,136,031 shares of Common Stock (approximately 8.8% of the Outstanding Common Stock). Of these shares, (i) 46,674,403 shares are held by ESBT S Trust and (ii) 10,461,628 shares are held by Pine Meadow Trust. Ms. Dumont has no voting control but shared dispositive control over these shares. Dr. Adelson, Mr. Chafetz and Ms. Dumont are co-trustees of ESBT S Trust. ESBT S Trust directly owns 46,674,403 shares of Common Stock (approximately 7.2% of the Outstanding Common Stock). Mr. Chafetz has the authority to vote the shares of Common Stock owned by this trust. Dr.Adelson, Mr. Chafetz and Ms. Dumont share dispositive control over the shares of Common Stock owned by this trust. Dr. Adelson and Mr. Chafetz are co-trustees of ESBT Y-II Trust. ESBT Y-II Trust directly owns 43,859,459 shares of Common Stock (approximately 6.8% of the Outstanding Common Stock). Mr. Chafetz has the authority to vote the shares of Common Stock owned by this trust. Dr. Adelson and Mr. Chafetz share dispositive control over the shares of Common Stock owned by this trust. Dr. Adelson and Mr. Chafetz are co-trustees of QSST A-II Trust. QSST A-II Trust directly owns 43,859,459 shares of Common Stock (approximately 6.8% of the Outstanding Common Stock). Mr. Chafetz has the authority to vote the shares of Common Stock owned by this trust. Dr. Adelson and Mr. Chafetz share dispositive control over the shares of Common Stock owned by this trust. Dr. Adelson and Mr. Chafetz are co-trustees of QSST M-II Trust. QSST M-II Trust directly owns 43,859,459 shares of Common Stock (approximately 6.8% of the Outstanding Common Stock). Mr. Chafetz has the authority to vote the shares of Common Stock owned by this trust. Dr. Adelson and Mr. Chafetz share dispositive control over the shares of Common Stock owned by this trust. Dr. Adelson and Mr. Chafetz are co-trustees of several trusts for the benefit of members of the Adelson family. These trusts directly own 292,674,960 shares of Common Stock. Dr. Adelson and Mr. Chafetz share authority to vote 2,208,548 shares of Common Stock owned by these trusts. Mr. Chafetz has sole authority to vote 290,466,412 shares of Common Stock owned by these trusts. Dr. Adelson and Mr. Chafetz share dispositive control over 238,485,060 shares of Common Stock owned by these trusts. Dr. Adelson has sole dispositive control over 54,189,900 shares of Common Stock owned by these trusts. Mr. Chafetz is the trustee of several trusts for the benefit of members of the Adelson family. These trusts directly own 43,864,929 shares of Common Stock. Mr. Chafetz has the sole authority to vote and sole dispositive control over the shares of Common Stock owned by these trusts. Dr. Adelson is the trustee of several trusts for the benefit of members of the Adelson family. These trusts directly own 48,206,373 shares of Common Stock and options to purchase 561,578 shares of Common Stock. Mr. Chafetz is a co-manager of a limited liability company for the benefit of members of the Adelson family, which directly owns 1,350,000 shares of Common Stock. Mr. Chafetz, as co-manager, shares dispositive control over these shares of Common Stock, and Mr. Chafetz has the sole authority to vote such shares. Mr. Chafetz disclaims beneficial ownership of these shares of Common Stock.

Item 5(c) of the Schedule 13D is hereby amended and restated as follows: Except as described in this Amendment, there have been no transactions by the Reporting Persons in shares of Common Stock since the filing of Amendment No. 15 to the Schedule 13D filed by the Reporting Persons on June 18, 2026.

Item 5(d) of the Schedule 13D is hereby amended and restated as follows: Except as set forth above regarding the beneficiaries and trustees of the trusts disclosed herein, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities set forth above.

Item 5(e) of the Schedule 13D is hereby amended by adding the text below to the end of Item 5(e) of the Schedule 13D. As of August 7, 2026, ESBT S-II Trust ceased to be the beneficial owner of more than five percent of the Outstanding Common Stock.